Last reviewed · How we verify

copper histidinate — Competitive Intelligence Brief

copper histidinate (copper histidinate) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Trace element supplement. Area: Metabolic/Genetic Disorders.

marketed Trace element supplement Copper ion (Cu2+) Metabolic/Genetic Disorders Small molecule Live · refreshed every 30 min

Target snapshot

copper histidinate (copper histidinate) — Sentynl Therapeutics, Inc.. Copper histidinate provides bioavailable copper to restore deficient copper levels in patients with copper malabsorption or deficiency.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
copper histidinate TARGET copper histidinate Sentynl Therapeutics, Inc. marketed Trace element supplement Copper ion (Cu2+)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Trace element supplement class)

  1. Sentynl Therapeutics, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). copper histidinate — Competitive Intelligence Brief. https://druglandscape.com/ci/copper-histidinate. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: